文献速递肝病消化道出血

卡维地洛与肝硬化患者生存改善相关:长期随访研究

Carvedilol is associated with improved survival in patients with cirrhosis: a long-term follow-up study.
PubMed 文献 · Aliment Pharmacol Ther · 2020-12-09

该研究对152例曾随机接受卡维地洛或食管静脉曲张套扎术(VBL)预防首次静脉曲张出血的肝硬化门脉高压患者进行最长20年回顾性随访。意向治疗分析显示卡维地洛组中位生存7.8年,VBL组4.2年(P=0.03),符合方案分析亦维持生存优势(P=0.02),无移植生存、肝相关死亡及失代偿事件两组相似。

要点

  • 卡维地洛组中位生存7.8年,优于VBL组4.2年(P=0.03)。
  • 符合方案分析中生存获益仍显著(P=0.02)。
  • 无移植生存、肝相关死亡及失代偿事件两组无差异。

核心结论

  • 卡维地洛可能为肝硬化门脉高压患者带来显著生存获益。
  • 全因死亡与肝相关死亡的差异提示生存获益可能不完全源于肝脏相关机制。

研究设计与样本

  • 回顾性分析152例来自多中心随机对照试验的患者,该试验于2000年4月7日至2006年6月24日招募,比较VBL与卡维地洛预防首次静脉曲张出血的疗效。
  • 利用电子记录进行最长20年长期随访,主要终点为全因死亡,次要终点为肝相关死亡和失代偿事件(腹水、肝性脑病、静脉曲张出血)。

主要发现

  • 意向治疗分析中,卡维地洛组中位生存7.8年,VBL组4.2年(P=0.03)。
  • 符合方案分析排除跨组患者后,生存获益仍显著(P=0.02)。
  • 无移植生存、肝相关死亡及失代偿事件两组相似。

临床怎么用

  • 对于肝硬化门脉高压患者,卡维地洛可作为预防首次静脉曲张出血的选项,并可能带来生存获益。

局限性

  • 本研究为回顾性长期随访分析,需前瞻性研究证实上述重要发现。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Primary prophylaxis of variceal haemorrhage with non-selective beta blockers (NSBB) or variceal band ligation (VBL) is now standard of care in patients with cirrhosis with portal hypertension. NSBB, and particularly carvedilol, may be associated with improved survival. AIM: To assess mortality in a cohort of patients previously randomised to either carvedilol or VBL. METHODS: We retrospectively analysed 152 patients recruited to a multi-centre randomised controlled trial between 7 April 2000 and 24 June 2006 designed to assess the efficacy of VBL versus carvedilol in preventing first variceal bleed. We used electronic records to undertake long-term follow-up (up to 20 years) with the primary outcome of all-cause mortality and secondary end points of liver-related mortality and decompensation events (ascites, encephalopathy, variceal bleeding). RESULTS: We included 152 patients in analysis with baseline characteristics well matched between the carvedilol (n = 77) and VBL (n = 75) groups. In the intention-to-treat analysis, carvedilol offered a significant survival advantage with median survival of 7.8 years compared to 4.2 years in the VBL group (P = 0.03). This survival benefit was maintained in per-protocol analysis when patients who crossed between treatment arms were excluded (P = 0.02). Transplant-free survival, liver-related mortality and decompensation events were similar in both groups. CONCLUSION: These data suggest that carvedilol offers a significant survival benefit for patients with cirrhosis and portal hypertension. The difference in all-cause and liver-related mortality suggests that this survival benefit may not be entirely liver-related. Prospective, studies are required to confirm these important findings.

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. McDowell HR, Chuah CS, Tripathi D, et al. Carvedilol is associated with improved survival in patients with cirrhosis: a long-term follow-up study. Aliment Pharmacol Ther. 2020. PMID: 33296526. doi:10.1111/apt.16189

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。